Metrion Biosciences, the specialist ion channel contract research and drug discovery group, has appointed Dr Barry Kenny and Dr Andrew Southan to its board of directors, a move that will see the group strengthen the company’s focus on commercial and business development capabilities.
Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.
He has held roles for Paradigm Therapeutics and Pfizer.
Dr Southan joined Metrion as head of commercial operations in October 2016, and was promoted to chief operating officer in April 2017.
He has over 25 years’ experience in ion channel research and development and has held roles for Wyeth Research and Ionix Pharmaceuticals.
Dr Keith McCullagh, non-executive chairman of Metrion Biosciences, said: “I am delighted to welcome both Barry and Andy to Metrion’s board of directors.
“Barry’s substantial experience of drug discovery deal-making will be of great value to Metrion as we continue to build our worldwide CRO and collaboration business, and Andy’s dedication to Metrion’s client service and quality of operations has been a major factor of growth of the business.”